Clinical Trials
20 trialsNCT06011772 2026-03-11
EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Active not recruiting
NCT07193862 2026-02-27
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Northwell Health
Phase EARLY_PHASE1 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04857684 2025-10-01
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT06557096 2024-08-16
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
Second Affiliated Hospital of Nanchang University
Phase EARLY_PHASE1 Not yet recruiting
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT01331616 2021-12-09
Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
West Penn Allegheny Health System
Phase EARLY_PHASE1 Withdrawn
NCT00949247 2020-07-27
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT02802098 2020-06-19
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase EARLY_PHASE1 Completed
NCT02072720 2019-10-02
Angiogenic Factor Expression During Fractionated Irradiation
Amsterdam UMC, location VUmc
Phase EARLY_PHASE1 Unknown
NCT02806817 2019-07-23
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
Centro Nacional de Investigaciones Oncologicas CARLOS III
Phase EARLY_PHASE1 Completed
NCT02768389 2019-03-15
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01086345 2018-07-03
Radiosurgery Plus Bevacizumab in Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01091792 2018-05-25
Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Completed
NCT00890786 2018-05-02
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT02446431 2015-05-18
Metronomic
Miller Children's & Women's Hospital Long Beach
Phase EARLY_PHASE1 Recruiting
NCT00140556 2013-01-18
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT01015300 2012-05-11
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Terminated